Anas Mansour

Anas Mansour

Auto-generated profile, based on publicly available information

Anas Mansour

Faculty of Medicine Al‐Azhar University Cairo Egypt

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 November 2025 in Pain Medicine
Verified
Journal Article
Closed access
AMAhmed Mansour
Ahmed Mansour
AAAhmed Mostafa Amin
Ahmed Mostafa Amin
AGAhmed Farid Gadelmawla
Ahmed Farid Gadelmawla
AEAhmed Elbataa
Ahmed Elbataa
AMAnas Mansour
Anas Mansour
AAAlaa Abd-Elsayed
Alaa Abd-Elsayed
Background and Objective: Pregabalin (PGB) and duloxetine (DLX) are commonly used first-line medications in the clinical management of painful diabetic neuropathy (PDN), yet high-quality comparative evidence is limited. This meta-analysis evaluates the comparative efficacy and safety of PGB versus DLX, focusing on efficacy outcomes such as pain reduction and mental health, and safety outcomes including adverse events in PDN patients. Method: We searched electronic databases for relevant studies assessing the efficacy and safety of PGB and DLX in PDN. The primary outcomes were the mean change of the Visual Analog Scale (VAS) and the improvement ratio for patients achieving ≥ 50% pain reduction. Secondary outcomes include the Numeric Rating Scale (NRS) for pain, the Short Form 12 Health Survey (SF-12), and related adverse events. A random-effects meta-analysis was performed to evaluate these outcomes. Results: We analyzed 19 studies involving 4483 patients. PGB significantly reduced VAS scores at 24 weeks (MD = -0.38; 95% confidence interval [CI], -0.45 to -0.31; P < .0001) and decreased the mental component of SF-12 compared to DLX (MD = -3.36; 95% CI, -6.64 to -0.07; P = .05) and lower rates of achieving >50% pain reduction (risk ratio = 0.88; 95% CI, 0.79 to 0.98; P = .03). Regarding safety, PGB showed a lower incidence of several adverse events, including anorexia, decreased appetite, diarrhea, nausea, and vomiting. However, no significant differences in VAS scores were observed between PGB and DLX at 1 week, 2 weeks, 4 weeks, 6 weeks, 8 weeks, and 12 weeks, with similar results observed in NRS. Conclusion: We found that PGB and DLX showed similar efficacy in relieving PDN. Ultimately, the 2 drugs’ similar effectiveness and different safety profiles highlight the importance of considering patient-specific factors when choosing the appropriate treatment.

9 September 2026 in Pacing and Clinical Electrophysiology
Verified
Journal Article
Closed access
PDF file
RSRida Shakeel
Rida Shakeel
AUAmmad Uddin
Ammad Uddin
DLDiksha Ladhani
Diksha Ladhani
KMKhubaib Tariq Mansoor
Khubaib Tariq Mansoor
AMAnas Mansour
Anas Mansour
HAHasibullah Aminpoor
Hasibullah Aminpoor

19 September 2026 in Multiple Sclerosis and Related Disorders
Verified
Journal Article
Closed access
YNYehia Nabil
Yehia Nabil
ASAhmed Shaheen
Ahmed Shaheen
AMAnas Mansour
Anas Mansour
ESEnas Kamal Abdalaziz Seyed
Enas Kamal Abdalaziz Seyed
BABaraah AbuAlsel
Baraah AbuAlsel
RSRam Saha
Ram Saha

26 May 2026 in International Journal of Stroke
Verified
Journal Article
Closed access
HMHamdy A. Makhlouf
Hamdy A. Makhlouf
AHAhmed Harb
Ahmed Harb
MAMoaz Elsayed Abouelmagd
Moaz Elsayed Abouelmagd
AMAnas Mansour
Anas Mansour
AOAhmed S.A. Osman
Ahmed S.A. Osman
JSJeffrey L Saver
Jeffrey L Saver
Background: Early antiplatelet therapy after intravenous thrombolysis (IVT) in acute ischemic stroke (AIS) patients may prevent re-occlusion and early neurological deterioration, but it could increase hemorrhagic transformation. Evidence remains conflicting, particularly with emerging contemporary trials. Methods: We conducted a Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA)-guided systematic review of randomized controlled trials (RCTs) comparing early antiplatelet therapy (eAPT) initiated within 24 h after IVT (with or without thrombectomy) versus standard timing (>24 h), placebo, or no antiplatelet therapy (CRD420251276445). Random-effects models were used to estimate odds ratios (ORs) and mean differences (MDs) with 95% confidence intervals (CIs). Trial sequential analysis, subgroup analyses, meta-regression, and Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) certainty ratings were performed. Results: Twelve RCTs with 4595 patients were included. Early antiplatelet therapy led to higher non-significant odds of symptomatic intracranial hemorrhage (sICH; OR = 1.68, 95% CI = 0.94–3.01; I 2 = 10.4%; GRADE moderate), and mortality (OR = 1.15, 95% CI = 0.83–1.58; I 2 = 14.8%; GRADE moderate) but not intracranial hemorrhage (OR = 1.01, 95% CI = 0.64–1.60; I 2 = 52.6%; GRADE low). Functional outcomes were not improved: Modified Rankin Scale (mRS) 0–1 (OR = 1.10, 95% CI = 0.83–1.46; I 2 = 60.5%; GRADE low) and mRS 0–2 (OR = 1.27, 95% CI = 0.89–1.80; I 2 = 73.4%; GRADE very low). Trial sequential analysis indicated evidence remains inconclusive. Agent-specific subgroup analyses suggested higher sICH with early aspirin (OR = 2.13, 95% CI = 1.02–4.45) and possible benefit for mRS 0–2 with tirofiban (OR = 2.07, 95% CI = 1.25–3.43). Conclusion: Routine early antiplatelet therapy within 24 h after IVT does not provide conclusive functional benefit, and our analysis cannot exclude clinically meaningful hemorrhagic harm. Further adequately powered RCTs are needed to define whether any selected regimen—especially tirofiban—has a favorable risk–benefit profile.

11 August 2026 in Pacing and Clinical Electrophysiology
Verified
Journal Article
Open access
PDF file
EMElsayed S. Moubarak
Elsayed S. Moubarak
AGAhmed Farid Gadelmawla
Ahmed Farid Gadelmawla
AMAlMothana Manasrah
AlMothana Manasrah
AMAnas Mansour
Anas Mansour
MEMohamed S. Elgendy
Mohamed S. Elgendy
HEHassan El-Shirbiny
Hassan El-Shirbiny
Background: In Wolff–Parkinson–White (WPW) syndrome, accurate localization of accessory pathways before catheter ablation can improve procedural planning and efficiency. Several 12‐lead electrocardiographic (ECG) algorithms have been proposed, but their diagnostic performance has not been consistently established. We performed a systematic review and meta‐analysis to assess the accuracy of ECG‐based algorithms for accessory pathway localization in manifest WPW. Methods: Following PRISMA‐DTA recommendations, PubMed, EMBASE, Cochrane CENTRAL, Web of Science, and Scopus were searched from January 1990 to January 2026. Studies enrolling adult or pediatric patients with manifest pre‐excitation who underwent electrophysiological study (EPS) and catheter ablation were included. Successful localization during EPS/ablation served as the reference standard. Random‐effects models were used to calculate pooled diagnostic accuracy, sensitivity, specificity, and diagnostic odds ratios (DOR). Summary receiver operating characteristic and leave‐one‐out sensitivity analyses were also performed. Results: Seventeen studies involving 3159 patients met inclusion criteria. The pooled diagnostic accuracy of ECG algorithms was 0.91 (95% CI 0.85–0.94), although heterogeneity was substantial (I 2 = 91.4%). Pooled sensitivity was 0.87 (95% CI 0.73–0.94), and pooled specificity was 0.98 (95% CI 0.95–0.99; I 2 = 0%). The pooled DOR was 297.17 (95% CI 46.33–1906.19; p <0.0001). Sensitivity analyses showed stable results after sequential exclusion of individual studies. Conclusion: Twelve‐lead ECG algorithms provide high diagnostic performance for accessory pathway localization in manifest WPW and may be useful adjuncts for pre‐ablation planning, although invasive electrophysiological mapping remains essential.